- Home
- IDYA vs PPTA Comparison
IDYA vs PPTA Comparison
Compare IDYA & PPTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- PPTA
- Stock Information
- Founded
- IDYA 2015
- PPTA 2011
- Country
- IDYA United States
- PPTA United States
- Employees
- IDYA N/A
- PPTA N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- PPTA Precious Metals
- Sector
- IDYA Health Care
- PPTA Basic Materials
- Exchange
- IDYA Nasdaq
- PPTA Nasdaq
- Market Cap
- IDYA 2.3B
- PPTA 1.9B
- IPO Year
- IDYA 2019
- PPTA N/A
- Fundamental
- Price
- IDYA $27.16
- PPTA $18.43
- Analyst Decision
- IDYA Buy
- PPTA Strong Buy
- Analyst Count
- IDYA 14
- PPTA 4
- Target Price
- IDYA $49.17
- PPTA $23.38
- AVG Volume (30 Days)
- IDYA 953.6K
- PPTA 1.9M
- Earning Date
- IDYA 11-03-2025
- PPTA 08-13-2025
- Dividend Yield
- IDYA N/A
- PPTA N/A
- EPS Growth
- IDYA N/A
- PPTA N/A
- EPS
- IDYA N/A
- PPTA N/A
- Revenue
- IDYA $7,000,000.00
- PPTA N/A
- Revenue This Year
- IDYA $62.30
- PPTA N/A
- Revenue Next Year
- IDYA $285.58
- PPTA N/A
- P/E Ratio
- IDYA N/A
- PPTA N/A
- Revenue Growth
- IDYA N/A
- PPTA N/A
- 52 Week Low
- IDYA $13.45
- PPTA $7.81
- 52 Week High
- IDYA $39.30
- PPTA $19.75
- Technical
- Relative Strength Index (RSI)
- IDYA 70.30
- PPTA 57.75
- Support Level
- IDYA $24.04
- PPTA $17.82
- Resistance Level
- IDYA $25.39
- PPTA $19.75
- Average True Range (ATR)
- IDYA 1.05
- PPTA 0.89
- MACD
- IDYA 0.16
- PPTA -0.02
- Stochastic Oscillator
- IDYA 99.45
- PPTA 61.96
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About PPTA Perpetua Resources Corp.
Perpetua Resources Corp is focused on the exploration, site restoration, and redevelopment of gold-antimony-silver deposits in the Stibnite-Yellow Pine district of central Idaho that are encompassed by the Stibnite Gold Project. The Project is one of the highest-grade, open-pit gold deposits in the United States and is designed to apply a modern, responsible mining approach to restore an abandoned mine site and produce both gold and the only mined source of antimony in the United States. It has one segment, mineral exploration in the United States.